

S2 Table. Comparison of different brands of praziquantel (PZQ) on the pharmacokinetic (PK) parameters in a rodent model. The brands, when named, were listed in subscript; P: Pure PZQ, T3A: T3A Pharmaceuticals Company PZQ, BILT: Biltricide, DIS: Distocide, BILH: Bilharzid, EPI: Epiquantel. The superscript descriptions show the additional information of the study. R: Rat, HR: Healthy Rat, M: Mouse, HM: Healthy Mouse, PB-PZQ: Polymorph B, (a): PID30 (male), (b): PID30 (female), (c): PID55 (male), (d): PID55 (female), (e): Pre-dosed with THIO and in a fasted state, (f): PZQ-susceptible *S. mansoni* isolate CD, (g): PZQ-non-susceptible *S. mansoni* isolate EE2 and BANL. Unless otherwise stated the following acronyms represent; AUC: Area under the plasma concentration-time curve, B (AUC_{0-inf}): Area under the plasma concentration-time curve extrapolated from time zero to infinity, t_{1/2}: Elimination half-life, C_{max}: Peak plasma concentration, T_{max}: Time to reach peak plasma concentration following drug administration.

Drug Administered	Drug Measured	PZQ Dose (mg/kg)	N	t _{1/2} (1/h)	T _{max} (h)	C _{max} (ng/ml)	AUC (ng/ml/h)
PZQ ^[1]		10					
HR	PZQ		6	1.54	0.58	377	441
HR	(R)- PZQ		6	1.08	0.5	168	177
PZQ ^[2]		25					
R ^(e)	PZQ		5	0.55	0.65	900	-
PZQ ^[3]		50					
M ^(mansoni)	(R)- PZQ		4	5.9	0.5	700	2200 ^B (ng*h/mL)
M ^(mansoni)	(S)- PZQ		4	5.5	0.5	200	3600 ^B (ng*h/mL)
PB-PZQ							
M ^(mansoni)	(R)- PZQ		4	5.4	0.5	200	400 ^B (ng*h/mL)
M ^(mansoni)	(S)- PZQ		4	5.4	0.5	100	300 ^B (ng*h/mL)
PZQ ^[3]		100					
M ^(mansoni)	(R)- PZQ		4	2.6	0.5	700	1300 ^B (ng*h/mL)
M ^(mansoni)	(S)- PZQ		4	0.4	0.5	100	300 ^B (ng*h/mL)
PB-PZQ ^[3]							
M ^(mansoni)	(R)- PZQ		4	10.6	0.5	300	1900 ^B (ng*h/mL)
M ^(mansoni)	(S)- PZQ		4	20.4	0.5	100	1600 ^B (ng*h/mL)
PZQ ^[3,4]	PZQ	200					
M ^(a) (mansoni)			7		0.46	31598	19650
M ^(b) (mansoni)			7		0.64	34168	40583
M ^(c) (mansoni)			7		0.4	26433	81017
M ^(d) (mansoni)			7		0.63	27473	76833
M ^(mansoni)	(R)- PZQ		4	3.3	0.8	2100	7100 ^B (ng*h/mL)

PB-PZQ ^[3]	<i>M</i> ^(a) (<i>mansoni</i>)	(S)- PZQ	4	6	0.8	2900	11500 ^B (ng*h/mL)
	<i>M</i> ^(b) (<i>mansoni</i>)	(R)- PZQ	4	3.1	0.5	900	
	<i>M</i> ^(c) (<i>mansoni</i>)	(S)- PZQ	4	1.5	0.5	400	3000 ^B (ng*h/mL) 1000 ^B (ng*h/mL)
PZQ ^[3]			300				
PB-PZQ ^[3]	<i>M</i> ^(a) (<i>mansoni</i>)	(R)- PZQ	4	5.9	0.5	800	2500 ^B (ng*h/mL)
	<i>M</i> ^(b) (<i>mansoni</i>)	(S)- PZQ	4	6.4	0.5	300	1000 ^B (ng*h/mL)
PB-PZQ ^[3]	<i>M</i> ^(a) (<i>mansoni</i>)	(R)- PZQ	4	4	0.8	900	3100 ^B (ng*h/mL)
	<i>M</i> ^(b) (<i>mansoni</i>)	(S)- PZQ	4	5.4	0.8	200	900 ^B (ng*h/mL)
PZQ ^[3,4]		PZQ	400				
PB-PZQ ^[3]	<i>M</i> ^(a) (<i>mansoni</i>)		7		0.4	35996	57700
	<i>M</i> ^(b) (<i>mansoni</i>)		7		0.64	58458	114383
	<i>M</i> ^(c) (<i>mansoni</i>)		7		0.4	31846	132800
	<i>M</i> ^(d) (<i>mansoni</i>)		7		0.63	51399	146017
	<i>M</i> ^(a) (<i>mansoni</i>)	(R)- PZQ	4	3.3	0.8	2700	6400 ^B (ng*h/mL)
	<i>M</i> ^(b) (<i>mansoni</i>)	(S)- PZQ	4	4.7	0.8	500	1900 ^B (ng*h/mL)
PB-PZQ ^[3]	<i>M</i> ^(a) (<i>mansoni</i>)	(R)- PZQ	4	5.3	0.5	1600	3100 ^B (ng*h/mL)
	<i>M</i> ^(b) (<i>mansoni</i>)	(S)- PZQ	4	7.1	0.5	700	1500 ^B (ng*h/mL)
PZQ ^[5]		PZQ	500				
PZQ ^[6]	<i>M</i> ^(f) (<i>mansoni</i>)		77	1.11	0.087	33330	42920
	<i>M</i> ^(g) (<i>mansoni</i>)		77	0.89	0.084	23440	26990
	<i>M</i> ^(g) (<i>mansoni</i>)		77	0.93	0.076	18600	11280
PZQ ^[6]	<i>HM</i> _(P)		11	1.05	0.11	14840	12260
	<i>HM</i> _(T3A)		11	0.46	0.12	10630	8350
	<i>HM</i> _(DIS)		11	0.78	0.08	12790	10190
	<i>HM</i> _(BILT)		11	1.18	0.11	13210	11100
	<i>HM</i> _(BILH)		11	0.42	0.08	11000	6620
	<i>HM</i> _(EP)		11	0.52	0.09	10790	8290

References

1. Zhang DL, Wang HN, Ji JB, Nie L, Sun DQ. A quantification method for determination of racemate praziquantel and R-enantiomer in rat plasma for comparison of their pharmacokinetics. *Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences*. 2017;1048:64-9. doi: 10.1016/j.jchromb.2017.02.013. PubMed PMID: WOS:000397686500008.
2. Kokwaro GO, Taylor G. Effect of experimentally-induced hepatic cirrhosis on the pharmacokinetics of orally administered praziquantel in the rat. *European journal of drug metabolism and pharmacokinetics*. 1990;15(3):199-202. Epub 1990/07/01. doi: 10.1007/bf03190204. PubMed PMID: 2253649.
3. Lombardo FC, Perissutti B, Keiser J. Activity and pharmacokinetics of a praziquantel crystalline polymorph in the *Schistosoma mansoni* mouse model. *European Journal of Pharmaceutics and Biopharmaceutics*. 2019;142:240-6. doi: <https://doi.org/10.1016/j.ejpb.2019.06.029>.
4. Gotardo MA, Hyssa JT, Carvalho RS, De-Carvalho RR, Gueiros LS, Siqueira CM, et al. Modulation of expression and activity of cytochrome P450s and alteration of praziquantel

kinetics during murine schistosomiasis. *Memorias Do Instituto Oswaldo Cruz*. 2011;106(2):212-9. doi: 10.1590/s0074-02762011000200016. PubMed PMID: WOS:000289961100016.

5. Botros SS, El-Din SHS, El-Lakkany NM, Sabra ANA, Ebeid FA. Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring *Schistosoma mansoni* isolates of different drug susceptibilities. *Journal of Parasitology*. 2006;92(6):1344-9. doi: 10.1645/ge-865r.1. PubMed PMID: WOS:000243959800032.

6. Botros S, El-Lakkany N, el-Din SHS, Sabra AN, Ibrahim M. Comparative efficacy and bioavailability of different praziquantel brands. *Experimental parasitology*. 2011;127(2):515-21. doi: 10.1016/j.exppara.2010.10.019. PubMed PMID: WOS:000286643300029.